Skip to main content
. Author manuscript; available in PMC: 2018 Mar 1.
Published in final edited form as: Am J Transplant. 2016 Sep 6;17(3):646–656. doi: 10.1111/ajt.13999

Figure 1. Treatment of ATG/Tac/Rapa or aCD40/Rapa based on regimen.

Figure 1

Two to three weeks before simultaneous islet and kidney transplantation (SIK), all seven cynomolgus monkey recipients received streptozotocin (75 mg/kg) for induction of diabetes. (A) Two cynomolgus monkey recipients received 4 doses of anti-thymocyte globulin (ATG: 3, 6, 10, 10 mg/kg) on days −2, −1, 0, and 1 relative to SIK. Daily tacrolimus (trough; 15~20 ng/ml) and rapamycin (trough; 10~15 ng/ml) were administered starting from day 0. (B) Five cynomolgus monkey recipients received 5 doses of anti-CD40 monoclonal antibody (mAb) (2C10R4: 20 mg/kg) on days 0, 2, 5, 7, and 9 relative to SIK, and 10 mg/kg weekly thereafter. Daily rapamycin (trough; 10~15 ng/ml) was given from day 0. Anti-inflammatory therapies including anti-IL-6R mAb (10 mg/kg) on days 0 and 5, and anti-TNF alpha mAb (25 mg) on days 0, 3, 7, and 10 were given in both groups.